Loss-of-function mutations of RUNX1 have been found in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs). Although several reports have suggested roles for RUNX1 as a tumor suppressor, its precise function remains unknown. Because gene alterations of RUNX1 by themselves do not lead to the development of leukemia in mouse models, additional mutation(s) would be required for leukemia development. Here, we report that the C-terminal deletion mutant of RUNX1, RUNX1dC, attenuates DNA-damage repair responses in hematopoietic stem/progenitor cells. cH2AX foci, which indicate the presence of DNA double-strand breaks, were more abundantly accumulated in RUNX1dC-transduced lineage
Introduction
Myelodysplastic syndromes (MDSs) are clonal hematological disorders derived from gene alterations at the level of hematopoietic stem cells, which are characterized by ineffective hematopoiesis, dysplastic morphology of blood cells and a high possibility of transition to acute myeloid leukemia (AML). A number of genetic or epigenetic alterations involved in the pathogenesis of MDS have been identified: activating point mutations of signaling molecules such as N-RAS and FLT3; 1 deletion, point mutations and/or silencing of cell cycle inhibitory molecules such as p15 and p53; 2,3 deletion, point mutations and generation of chimeric genes from transcriptional factors such as EVI-1 and RUNX1; 4, 5 and point mutations of nuclear proteins such as nucleophosmin and TET2. 6, 7 Among these changes, point mutations of RUNX1 have been detected in about 10-20% of patients classified as MDS/AML (high-risk MDS and AML following MDS). 5 The transcription factor RUNX1 and its heterodimeric partner core-binding factor (CBF)b (also known as phosphatidylethanolamine-binding protein2b) comprise CBFs. CBFs are the most frequent targets of gene rearrangement and mutation in human leukemias; leukemias harboring mutations in either subunit of a CBF are commonly called CBF leukemias. 8 Recently, Tang et al. 9 reported RUNX1 mutations were detected in 13.2% of 470 adult patients with de novo AML. In addition, hereditary loss-of-function mutations of RUNX1 cause familial platelet disorder with predisposition to AML, which is characterized by decreased platelet count and propensity to develop AML. 10 These findings suggest RUNX1 works as a tumor suppressor and impaired RUNX1 function promotes leukemia development. Nonetheless, RUNX1 deletion or dominant-negative inhibition of RUNX1 by itself is not sufficient for leukemia development in several mouse models, 11, 12 indicating that additional cooperating events are required. However, the mechanisms by which impaired RUNX1 functions lead to subsequent genetic alterations are not fully understood.
Cells in the human body are always exposed to DNA stresses, which induce damages to chromosomal DNA. 13 Physiological stresses such as hydrolytic reactions, non-enzymatic methylations and oxygen radicals generate DNA-base lesions. 14 Environmental agents such as ultraviolet (UV), ionizing radiation and a lot of genotoxic chemicals also induce DNA damages including single-and double-strand breaks (DSBs). These DNA lesions are repaired through damage-specific repair pathways. However, if these lesions are left unrepaired, these cells alone and/or in combination with additional mutations would have a higher risk of tumor development. 15 In a previous study, it was reported that Runx1-deficient mice had an increased incidence of hematological malignancy compared with wildtype (WT) mice after treatment with the mutagen, N-ethyl-N-nitrosourea. 16 We speculated RUNX1 might have a role in the DNA-damage repair (DDR) response. Here, we show that a C-terminal deletion mutant of RUNX1, RUNX1dC, enhances DNA-damage accumulation in hematopoietic stem cell-enriched lineage À Sca1 þ c-kit þ (LSK) cells. Furthermore, we found RUNX1dC attenuates the DDR response after exposure to DNA-damage agents. As for this mechanism, we found that RUNX1dC suppresses the transcription of a sensor of DNA stress, Gadd45a. 17 Moreover, bone marrow (BM) cells from MDS/ AML patients harboring a RUNX1-C-terminal mutation showed significantly lower GADD45A expression than those from MDS/ AML patients with WT RUNX1. These results suggest RUNX1
regulates Gadd45a transcription and impaired RUNX1 function can cause additional mutation(s) required for multi-step leukemogenesis.
Materials and methods

Real-time (RT)-PCR array
Total cellular RNA was extracted from 4 Â 10 6 cells using the RNeasy Mini Kit (Qiagen, Tokyo, Japan). A total of 4 mg of RNA was reverse-transcribed into cDNA using the RT 2 First Strand Kit (SABiosciences, Frederick, MD, USA) and subjected to RT-PCR array analysis (RT 2 Profiler PCR Array: Mouse DNA Damage Signaling, SABiosciences). Gene expression profiles of 32D-neo and 32D-RUNX1dC cells were analyzed by the DDCt method.
Colony-forming assay
32D-neo and 32D-RUNX1dC cells (1 Â 10 5 cells) were suspended in 500 ml of phosphate buffered saline and exposed to UV-B (800 or 1600 J/m 2 ). 
Statistical analysis
All values are expressed as means±s.e.m. We performed statistical analysis using Student's t-test. Values were considered statistically significant at Po0.05.
Results
RUNX1dC induces DNA-damage accumulation in LSK cells
DNA-damage accumulation and its repair pathways have important roles in tumor development. 13 Thus, we first evaluated DNA-damage accumulation in a C-terminal truncated RUNX1 mutant-transduced LSK cells. In this study, we utilized the RUNX1dC, which lacks 225 amino acids covering both transactivating and transrepressing domains of WT RUNX1 ( Figure 1a ). This mutant was originally identified in a patient with MDS, and we and others previously showed it functions as a dominant-negative mutant over WT RUNX1 (RUNX1b) by inhibiting its DNA-binding activity. 20, 21 RUNX1dC resembles in size an isoform of RUNX1, RUNX1a, (Figure 1a) , which also has an inhibitory effect against RUNX1b. 22 Two days after gene transduction, we evaluated accumulations of DSBs using an antibody recognizing the phosphorylated histone variant H2AX at serine 139 (gH2AX). 23 As 
RUNX1dC transduction results in the attenuation of the DDR response to DSBs in LSK cells
We next examined the DDR response in RUNX1dC-transduced LSK cells after exposure to environmental stressors. gH2AX foci, which indicate the immediate chromatin modification in RUNX1 mutation attenuates DNA-damage response Y Satoh et al response to the formation of DSBs, reached a peak 30-60 min after irradiation (Figure 2a) . Thereafter, the number of foci decreased with a half-life of several hours due to the DNA-repair response to DSBs. 24 Therefore, sustained accumulation of gH2AX foci indicates attenuation of the DDR response to DSBs. A total of 6 h after g-ray treatment, RUNX1dC-transduced cells showed significantly higher accumulation of gH2AX foci than Mock-transduced LSK cells (P ¼ 0.0112; Figure 2b ). Moreover, although the percentage of multiple foci-positive cells carrying more severe accumulations of DSBs was only 37.6% among gH2AX-positive cells in Mock transduction, most (93.5%) gH2AX-positive cells had multiple foci in RUNX1dC-transduced LSK cells (Figure 2b right panel) . In addition, we analyzed the colony-forming ability of Mock-or RUNX1dC-transduced LSK cells after treatment with UV-B. In this assay, the DDR response of tested cells can be measured by relative colony numbers because only cells that recovered from DNA damage can make colonies. 25 At steady state, there was no significant difference in colony-forming ability between Mock-and RUNX1dC-transduced LSK cells (Figure 2c 
RUNX1dC suppresses Gadd45a expression in LSK cells
As DSBs were more prominent in RUNX1dC-transduced LSK cells than in Mock-transduced LSK cells, we speculated that the defect in the DDR response gene may be a cause of enhanced DNA-damage accumulation in RUNX1dC-transduced LSK cells. Therefore, we next examined whether RUNX1dC alters expressions of DNA-damage signaling molecules. We prepared 32Dcl3 cells expressing RUNX1dC and confirmed expression by immunoblot (Supplementary Figure 1) . We profiled the expression of 84 genes involved in DNA-damage signaling by RT-PCR array using this subclone. Before performing the RT-PCR array experiment, we confirmed 32D-RUNX1dC showed significantly lower colony-forming ability than 32D-neo cells after UV-B exposure, just like RUNX1dC-transduced LSK cells (at 1600 J/m 2 : 38.2% in 32D-RUNX1dC vs 67.2% in 32D-neo, Po0.0234; Figure 3a right panel) . Furthermore, we evaluated the accumulation of cyclobutane pyrimidine dimers, which are major products of DNA damage induced by UV-B, in 32D-neo and 32D-RUNX1dC cells. 26 There was no distinct difference in cyclobutane pyrimidine dimer accumulation between 32D-neo and 32D-RUNX1dC cells before UV-B treatment (Figure 3b) . Although 1 h after UV-B treatment the levels of cyclobutane pyrimidine dimer accumulation were the same in 32D-neo and 32D-RUNX1dC cells, the removal of cyclobutane pyrimidine dimer was significantly impaired in 32D-RUNX1dC cells compared with 32D-neo (Figure 3b ). In addition, as with RUNX1dC-transduced LSK cells, 32D-RUNX1dC cells showed sustained accumulation of gH2AX foci after g-ray irradiation (Figure 4b ). After correction using five housekeeping genes (Gusb, Hprt1, Hsp90ab1, Gapdh and Actb), we obtained four candidate genes, in which expression was repressed in 32D-RUNX1dC cells compared with 32D-neo cells with a fold-difference cutoff of o0.5 (Figure 3c and Supplementary Table 1 ). Among these candidate genes, the expression of Gadd45a was particularly decreased in 32D-RUNX1dC cells compared with 32D-neo cells (Figure 3c and Supplementary  Figure 2a) . Quantitative RT-PCR using 32D-RUNX1dC and 32D-neo cells confirmed the expression of Gadd45a was significantly lower (42%) in 32D-RUNX1dC cells than in 32D-neo cells (Supplementary Figure 2b) . To examine if this result was relevant to normal LSK cells, we also examined the expression of Gadd45a in RUNX1dC-transduced LSK cells. RUNX1dC-transduced LSK cells showed significantly lower expression (44%) of Gadd45a than Mock-transduced LSK cells (Figure 3d ). LSK cells, which were transduced with a RUNX1 mutant harboring a point mutation in the Runt homology domain (D171N) 19,21 also showed significantly lower (53%) expression of Gadd45a compared with Mock-transduced LSK (Figure 3d ). Moreover, WT RUNX1-transduced LSK cells expressed more Gadd45a, an increase of 108% relative to Mock-transduced LSK cells (Figure 3d ). To examine whether the impaired colony-forming ability of 32D-RUNX1dC cells attributed to the repressed expression of Gadd45a by RUNX1dC, we introduced the expression vector for Gadd45a into 32D-RUNX1dC cells, which was named 32D-RUNX1dC-Gadd45a (Supplementary Figure 3a) . Consistent with the report from Perugini et al., 27 Gadd45a overexpression reduced the cell proliferation ability at steady state (Figure 4a left panel) . After UV-B treatment, exogenously expressed Gadd45a restored the colony-forming ability in 32D-RUNX1dC-Gadd45a cl1 cells (32D-RUNX1dC-GFP, 21.8%; 32D-RUNX1dC-Gadd45a cl1, 132%; Figure 4a right panel) . Similar results were obtained from two other clones (Supplementary Figure 3b) . Furthermore, we found exogenously expressed Gadd45a reduced gH2AX-positive foci in 32D-RUNX1dC-Gadd45a cl1 cells compared with 32D-RUNX1dC-GFP cells after UV-B treatment (Figure 4b ). In addition, the reduction of gH2AX-positive foci in 32D-RUNX1dC-Gadd45a cl1 cells was also observed at steady state (Supplementary Figure 3c) .
RUNX1 transcriptionally regulates Gadd45a expression
To analyze the mechanism by which RUNX1 regulates Gadd45a expression, we utilized luciferase assays using a human myeloid leukemia cell line UT-7/GM. Although there was no consensus sequence for RUNX binding in the 5 0 -flanking region of the human GADD45A gene, we found two RUNXbinding sequences neighboring the p53-binding site in RUNX1 mutation attenuates DNA-damage response Y Satoh et al intron 3 of the GADD45A gene. Intron 3 is highly conserved between humans and rodents, and p53 transcriptionally activates GADD45A expression through this p53-binding site. 28, 29 Therefore, we generated three types of luciferase reporter genes covering this region. Intron 3A-Luc contained the two RUNXbinding sequences (at þ 1469 and þ 1566) of the human GADD45A gene. Intron 3B-Luc contained only the upstream binding sequence ( þ 1469) and intron 3C-Luc contained only the downstream binding sequence ( þ 1566; Figure 5a ). RUNX1b together with its heterodimerization partner CBFb activated intron 3A-Luc, intron 3B-Luc and intron 3C-Luc 11.2-fold, 8.6-fold, and 3.2-fold, respectively (Figure 5b ). The 1469 MT-Luc and 1566 MT-Luc constructs, which have one mutated RUNX-binding sequence (TGTGGT changed to TGTTAG), showed reduced reporter activity by RUNX1b compared with intron 3A-Luc (7.3-fold activation in 1469 MT-Luc and 6.1-fold activation in 1566 MT-Luc, Figures 5a and b) . Furthermore, the 1469/1566 MT-Luc construct, which has two mutated RUNX-binding sequences, showed a 63% reduction of reporter activity by RUNX1 compared with intron 3A-Luc (4.1-fold activation). In addition, the co-expression experiment with RUNX1b and p53 revealed these two genes synergistically activate the intron 3A-Luc construct (only p53: 59.6-fold activation and p53 with RUNX1: 108.4-fold activation; Figure 5c ). We also examined the change in intron 3A-Luc activation by RUNX1b and/or p53 after g-ray irradiation; yet, there was no difference in reporter activities between g-ray irradiated and non-irradiated UT-7/GM cells (data not shown). Next, we examined the co-expression effects of RUNX1 mutants on GADD45A-reporter activation with RUNX1b. We had to transfect high amount of DNA into test cells; therefore we utilized the adherent cell line, 293T, to perform the luciferase assay. 20 Single transduction experiment of RUNX1dC revealed RUNX1dC showed reduced GADD45A-reporter activity compared with the transduction of RUNX1b (10-fold activation in RUNX1b and 5-fold activation in RUNX1dC). In the case of the D171N mutant, the D171N mutant did not show the significant GADD45A-reporter activity (3.3-fold) compared with back-bone reporter activity (2.9-fold). In addition, we found RUNX1b-induced intron 3A-Luc activity was reduced to 55% by RUNX1dC and to 37% by the D171N mutant (Supplementary Figure 4) . To test whether endogenous RUNX1 binds to the GADD45A gene in vivo, we conducted ChIP assays using the nuclear extract of UT-7/GM cells. As shown in Figure 5d , the two RUNX-binding sequences were immunoprecipitated with the anti-RUNX1 antibody but not by control IgG. Together, these data indicate that endogenous RUNX1 binds to two RUNX1-binding sites in intron 3 of the GADD45A gene, thereby regulating its transcription.
GADD45A expression is significantly decreased in MDS/AML patients harboring RUNX1-C-terminal mutations compared with those with WT RUNX1
Finally, we evaluated GADD45A expression in BM mononuclear cells from 23 MDS/AML patients with or without RUNX1 C-terminal mutations and from 10 controls. 19 We found BM mononuclear cells from MDS/AML patients harboring RUNX1-C-terminal mutations had significantly lower GAD-D45A expression compared with those from MDS/AML patients with WT RUNX1 (P ¼ 0.0233; Figure 6 ).
Discussion
We found RUNX1 transcriptionally regulates Gadd45a. In our experiment using LSK cells, the expression of Gadd45a was reduced to 44% of that of control cells by RUNX1dC (Figure 3d ). This level of Gadd45a expression is roughly the same as that observed in Gadd45a þ /À mice, which do not develop spontaneous tumors but are susceptible to tumor development in response to mutagens because of genomic instability. 30 Like Gadd45a þ /À mice, heterozygous deletion of RUNX1 predisposes mice to AML when accompanied by other gene alterations. 31 The similar phenotypes of Gadd45a þ /À and RUNX1 þ /À mice raise the possibility that both molecules have closely related roles in maintaining genome stability. As for the relationship between RUNX1 and Gadd45a, Perugini et al. 27 recently reported that GADD45A expression was significantly downregulated in RUNX1-ETO-positive AML cells compared with normal controls. Although they demonstrated ERK1/2 signaling was involved in the repression of GADD45A in several AML cell lines, its mechanism was not analyzed in their study. In previous papers, RUNX1-ETO was shown to decrease the expression of several genes involved in the base excision repair pathway, such as oxoguanine DNA glycosylase and polymerase epsilon, thereby DNA damage accumulated. 32, 33 Gadd45a functions in the nucleotide excision repair pathway through its interaction with proliferating cell nuclear antigen; [34] [35] [36] therefore, both base excision repair and nucleotide excision repair might be impaired in hematopoietic cells carrying RUNX1 mutations. Gadd45a also functions as a stress sensor, which is mediated by a complex interplay of physical interactions with other cellular proteins that are implicated in cell-cycle regulation and the response of cells to stress. 17 Gupta et al. 37 reported that Gadd45a-deficient hematopoietic cells demonstrated an impaired DDR response. They found myeloidenriched BM cells from Gadd45a-or Gadd45b-deficient mice were defective in G2/M arrest following exposure to UV and VP-16 and these cells were sensitized to genotoxic-stressinduced apoptosis. 37 Similarly, we found that RUNX1dC-transduced LSK cells showed lower colony-forming ability than Mock-transduced LSK cells after UV-B exposure. Like RUNX1dC-transduced cells, Gadd45a expression was reduced in D171N-transduced LSK cells compared with Mock-transduced LSK cells (Figure 3d ). The D171N mutant does not have DNA-binding ability, whereas it still maintains the ability to bind to CBFb. 5 The co-expression experiment with D171N inhibited GADD45A reporter activation induced by RUNX1b (Supplementary Figure 4) ; therefore, it is possible that D171N inhibits the function of WT RUNX1 by trapping CBFb. Differences in the DDR response between N-terminal in-frame type mutations (such as the D171N mutant) and C-terminal truncated mutations (such as the RUNX1dC) of RUNX1 should be explored in a future study.
Gadd45a is a well known transcriptional target of p53. 29 p53 binds to the conserved sequence within intron 3 of the GADD45A gene in response to ionizing radiation. 29 Here, we showed that RUNX1 activates transcription of GADD45A through binding to two RUNX-binding sites neighboring the p53-binding site within intron 3 (Figure 5b ). RUNX1 and p53 showed synergistic effects on intron3A-Luc activation ( Figure 5c) ; therefore, these two molecules may cooperatively regulate GADD45A expression. In our experiment, however, g-ray irradiation did not influence intron 3A-Luc activation by RUNX1 and/or p53. We are now trying to examine the cooperating effect of RUNX1 and p53 on DDR response, including GADD45A regulation, using a more physiological setting.
MDS patients with a RUNX1 mutation frequently present with more advanced diseases and RUNX1 mutations are considered to be markers of a poor prognosis. 19, 38, 39 We speculate that a RUNX1 mutation may be a cause of additional mutation(s) through the impaired DDR response. In future studies, whole genome analysis of MDS/AML samples harboring RUNX1 mutations would clarify the role of RUNX1 mutations in the occurrence of genetic abnormalities in these patients.
In conclusion, we demonstrated that a RUNX1 C-terminal deletion mutant attenuates the DDR response to environmental and physiological stresses in LSK cells. As a possible explanation Figure 6 Expression levels of GADD45A in MDS/AML patients. Relative expression levels of GADD45A in BMMNCs from controls and MDS/AML patients with WT RUNX1 (RUNX1 wt) or C-terminal mutations (RUNX1 mut) are shown. Horizontal bar and value denotes mean GADD45A expressions (normalized to GAPDH). The patients' characteristics are shown in Supplementary Table 2.
RUNX1 mutation attenuates DNA-damage response Y Satoh et al for this mechanism, we found a novel role for RUNX1 in the transcriptional regulation of Gadd45a. The impaired Gadd45a function leads to genomic instability; therefore, Gadd45a dysfunction induced by RUNX1 mutations can cause the additional mutation(s) required for multi-step leukemogenesis. Further studies on RUNX1/Gadd45a would be useful to understand the pathophysiology of MDS/AML patients harboring RUNX1 abnormalities and to prevent disease progression.
